WallStSmart

Clearpoint Neuro Inc (CLPT)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 15421% more annual revenue ($6.30B vs $40.61M). EW leads profitability with a 17.4% profit margin vs -71.6%. CLPT appears more attractively valued with a PEG of 0.61. EW earns a higher WallStSmart Score of 61/100 (C+).

CLPT

Hold

37

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.3Quality: 5.0
Piotroski: 4/9Altman Z: -2.65

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 6.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLPTUndervalued (+10.6%)

Margin of Safety

+10.6%

Fair Value

$14.96

Current Price

$12.89

$2.07 discount

UndervaluedFair: $14.96Overvalued
EWUndervalued (+68.7%)

Margin of Safety

+68.7%

Fair Value

$253.29

Current Price

$85.96

$167.33 discount

UndervaluedFair: $253.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLPT2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
42.9%10/10

Revenue surging 42.9% year-over-year

PEG RatioValuation
0.618/10

Growing faster than its price suggests

EW4 strengths · Avg: 9.5/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

CLPT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$429.45M3/10

Smaller company, higher risk/reward

Price/BookValuation
20.5x2/10

Trading at 20.5x book value

Return on EquityProfitability
-154.3%2/10

ROE of -154.3% — below average capital efficiency

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.054/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
46.0x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : CLPT

The strongest argument for CLPT centers on Revenue Growth, PEG Ratio. Revenue growth of 42.9% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : CLPT

The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 3.37 is elevated, increasing financial risk.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.

Key Dynamics to Monitor

CLPT profiles as a hypergrowth stock while EW is a growth play — different risk/reward profiles.

CLPT carries more volatility with a beta of 1.31 — expect wider price swings.

CLPT is growing revenue faster at 42.9% — sustainability is the question.

CLPT generates stronger free cash flow (-9M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 37/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clearpoint Neuro Inc

HEALTHCARE · MEDICAL DEVICES · USA

ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.

Visit Website →

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?